Updated data from the NORSE trial of erdafitinib (ERDA) plus cetrelimab (CET) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and specific fibroblast growth factor receptor (FGFR) alterations

Simple item page
dc.conference.dateSEP 19-OCT 18, 2020
dc.conference.titleESMO Virtual Congress
dc.contributor.authorSiefker-Radtke, A. O.
dc.contributor.authorLoriot, Y.
dc.contributor.authorSiena, S.
dc.contributor.authorBeato, C.
dc.contributor.authorCliment Duran, M. A.
dc.contributor.authorVarlamov, S.
dc.contributor.authorDuran, I.
dc.contributor.authorTagawa, S. T.
dc.contributor.authorGeoffrois, L.
dc.contributor.authorMellado, B.
dc.contributor.authorSemenov, A.
dc.contributor.authorDelva, R.
dc.contributor.authorLykov, A. P.
dc.contributor.authorDirix, L. Y.
dc.contributor.authorAkapame, S.
dc.contributor.authorO'Hagan, A.
dc.contributor.authorTammaro, M.
dc.contributor.authorMosher, S.
dc.contributor.authorKang, T. W.
dc.contributor.authorMoreno, V.
dc.contributor.authoraffiliation[Siefker-Radtke, A. O.] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA
dc.contributor.authoraffiliation[Loriot, Y.] Univ Paris Saclay, Univ Paris Sud, Inst Gustave Roussy, Villejuif, France
dc.contributor.authoraffiliation[Siena, S.] Grande Osoped Metropolitano Niguarda, Med Oncol, Milan, Italy
dc.contributor.authoraffiliation[Siena, S.] Univ Milan, Milan, Italy
dc.contributor.authoraffiliation[Beato, C.] Hosp Univ Virgen Macarena, Oncol, Seville, Spain
dc.contributor.authoraffiliation[Climent Duran, M. A.] Inst Valenciano Oncol, Med Oncol, Valencia, Spain
dc.contributor.authoraffiliation[Varlamov, S.] Altai Reg Canc Ctr, Med Oncol, Barnaul, Russia
dc.contributor.authoraffiliation[Duran, I.] Hosp Univ Marques Valdecilla, Med Oncol, Santander, Spain
dc.contributor.authoraffiliation[Tagawa, S. T.] Weill Cornell Med, Dept Med Oncol, New York, NY USA
dc.contributor.authoraffiliation[Geoffrois, L.] Inst Cancerol Lorraine Alexis Vautrin, Med Oncol, Vandoeuvre Les Nancy, France
dc.contributor.authoraffiliation[Mellado, B.] Univ Barcelona, Hosp Clin Inst Invest Biomed August Pi & Sunye, Med Oncol Dept, Barcelona, Spain
dc.contributor.authoraffiliation[Semenov, A.] Ivanovo Reg Oncol Dispensary, Reg Budgetary Healthcare Inst, Med Oncol, Ivanovo, Russia
dc.contributor.authoraffiliation[Delva, R.] Inst Cancerol Ouest, Med Oncol, Angers, France
dc.contributor.authoraffiliation[Lykov, A. P.] Med City, State Autonomous Healthcare Inst Multidisciplinar, Tyumen, Russia
dc.contributor.authoraffiliation[Dirix, L. Y.] Univ Antwerp, GZA Ziekenhuizen Campus Sint Augustinus, Med Oncol, Antwerp, Belgium
dc.contributor.authoraffiliation[Akapame, S.] Janssen Res & Dev, Raritan, NJ USA
dc.contributor.authoraffiliation[O'Hagan, A.] Janssen Res & Dev, Spring House, PA USA
dc.contributor.authoraffiliation[Tammaro, M.] Janssen Res & Dev, Spring House, PA USA
dc.contributor.authoraffiliation[Mosher, S.] Janssen Res & Dev, Spring House, PA USA
dc.contributor.authoraffiliation[Kang, T. W.] Chonnam Natl Univ, Sch Med, Dept Urol, Gwangju, South Korea
dc.contributor.authoraffiliation[Moreno, V.] Fdn Jimenez Diaz Univ Hosp, START Madrid FJD, Clin Res Phase & Trials Unit, Madrid, Spain
dc.contributor.funderJanssen Research & Development, LLC
dc.date.accessioned2025-01-07T16:00:48Z
dc.date.available2025-01-07T16:00:48Z
dc.date.issued2020-09-01
dc.identifier.doi10.1016/j.annonc.2020.08.824
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttp://www.annalsofoncology.org/article/S0923753420408208/pdf
dc.identifier.urihttps://hdl.handle.net/10668/27557
dc.identifier.wosID573469101040
dc.issue.number4
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen del Rocío
dc.organizationSAS - Hospital Universitario Virgen Macarena
dc.page.numberS584-S585
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titleUpdated data from the NORSE trial of erdafitinib (ERDA) plus cetrelimab (CET) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and specific fibroblast growth factor receptor (FGFR) alterations
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number31
dc.wostypeMeeting Abstract

Files

Collections

SAS - Hospital Universitario Virgen del Rocío
SAS - Hospital Universitario Virgen Macarena

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía